A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune

MLA

Zhenzhen Jiang, et al. “A Combination of a TLR7/8 Agonist and an Epigenetic Inhibitor Suppresses Triple-Negative Breast Cancer through Triggering Anti-Tumor Immune.” Journal of Nanobiotechnology, vol. 22, no. 1, May 2024, pp. 1–21. EBSCOhost, https://doi.org/10.1186/s12951-024-02525-1.

APA

Zhenzhen Jiang, Guangqing Cai, Haiting Liu, Leping Liu, Rong Huang, Xinmin Nie, Rong Gui, Jian Li, Jinqi Ma, Ke Cao, & Yanwei Luo. (2024). A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune. Journal of Nanobiotechnology, 22(1), 1–21. https://doi.org/10.1186/s12951-024-02525-1

Chicago

Zhenzhen Jiang, Guangqing Cai, Haiting Liu, Leping Liu, Rong Huang, Xinmin Nie, Rong Gui, et al. 2024. “A Combination of a TLR7/8 Agonist and an Epigenetic Inhibitor Suppresses Triple-Negative Breast Cancer through Triggering Anti-Tumor Immune.” Journal of Nanobiotechnology 22 (1): 1–21. doi:10.1186/s12951-024-02525-1.